Akut limfoid leukémia (ALL): ki dolgozik rajta

Intézményenként egy kártya. Válassz célpontot, és csak az azon dolgozó csoportok maradnak.

• Minden célpont
• CD19 122
• CD22 33
• ABL1 10
• KMT2A 8
• CD20 8
• TP53 0
• AKT 0
• BCL-2 3
• PI3K 0
• CD123 5
• JAK 2
• CD38 4
• PD-1 3
• RUNX1 0
• mTOR 0
• NPM1 4
• BCMA 4
• NOTCH1 0
• CXCR4 1
• PTEN 0
• CTNNB1 0
• EGFR 0
• HDAC 0
• IDH 0
• MYC 0
• RAS 0
• STAT3 0
• AMPK 0
• CD30 0
• CD40 0
• CD47 0
• ERK 0
• FGFR 0
• MAPK 0
• MDM2 0
• PD-L1 0
• CD33 1
• FLT3 0
• IL-1 0
• IL-17 0
• IL-6 0
• KRAS 0
• MEK 0
• PPAR 0
• RANKL 0
• RB1 0
• TYK2 0
• ALK 0
• AXL 0
• BRCA1 0
• BRD4 0
• BTK 0
• CDK4/6 0
• CDKN2A 0
• CTLA-4 0
• EZH2 0
• FAK 0
• FTO 0
• GPRC5D 1
• GPX4 0

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  SMART-SMAPs: a new paradigm of cell-free cytotoxic immunotherapy for resistant CLL

  Universita Degli Studi di Siena· Siena, Olaszország· EU contribution 150 000 EUR· until 2028. márc.· 2 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-RIA

  TOWARDS THE ELIMINATION OF ACUTE LYMPHOBLASTIC LEUKAEMIA IN CHILDREN THROUGH IDENTIFICATION OF THEIR ENVIRONMENTAL CAUSES (ELI-ALL)

  Centre International de Recherche Sur Le Cancer· Lyon 7eme, Franciaország· EU contribution 6 502 240 EUR· until 2031. aug.· 12 countries

• European Commission (Horizon Europe) · HORIZON-RIA

  THERAPEUTIC ANTIBODIES NEUTRALIZING ALL THE ORTHOPOXVIRUS INFECTIOUS FOR HUMANS, INCLUDING SMALLPOX (THANATOS)

  Commissariat A L Energie Atomique Et Aux Energies Alternatives· Paris, Franciaország· EU contribution 13 557 641 EUR· until 2031. aug.· 6 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Role of RAS mutant subclones in the development of High Hyperdiploid B-ALL (RasWayToALL)

  Vib Vzw· Zwijnaarde - Gent, Belgium· EU contribution 200 400 EUR· until 2028. jún.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-CSA

  Science, Innovation, Health, Earth, And Life Technologies for ALL (SCIENCE4ALL)

  Istinye University· Istanbul, Törökország· EU contribution 350 000 EUR· until 2028. jún.

• European Commission (Horizon Europe) · HORIZON-CSA

  OUR SCIENCE - MAKING SCIENCE A SHARED JOURNEY FOR ALL (OUR_SCIENCE_26-27)

  Rannsoknamidstod Islands· Reykjavik, Izland· EU contribution 349 226 EUR· until 2028. máj.

• European Commission (Horizon Europe) · HORIZON-EIC-ACC

  PANDEMIC PREPAREDNESS THROUGH INTRANASAL ADMINISTRATION OF BROADLY EFFECTIVE MONOCLONAL ANTIBODIES AGAINST ALL INFLUENZA STRAINS (PanFlu)

  Leyden Laboratories Bv· Leiden, Hollandia· EU contribution 2 499 999 EUR· until 2027. okt.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Relapse in T-ALL: Resistant Clones and Therapeutical Options (RETRO)

  Fundacion Para la Gestion de la Investigacion En Salud de Sevilla· Sevilla, Spanyolország· EU contribution 181 153 EUR· until 2027. aug.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-EIC-ACC

  DUO 4 ALL

  Croivalve Limited· Dublin, Írország· EU contribution 2 493 375 EUR· until 2027. jan.

• European Commission (Horizon Europe) · HORIZON-EIC-ACC-BF

  The first IVDR-approved commercial software solutions for AI-powered RNA-based companion and precision cancer diagnostics of acute myeloid leukaemia and bladder cancer (QIandQD)

  Qlucore Ab· Lund, Svédország· EU contribution 2 491 650 EUR· until 2027. ápr.

  The disease is named only in the funder's project summary, not in the title.

10 of 13 running projects, newest first. Listed amounts together: 62,2 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

Ebben a nézetben egy vizsgálat sem jelzi, hogy megosztaná a résztvevői adatokat.

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 6
• Mendelian Randomization Analysis 4
• CRISPR-Cas Systems 5
• Gene Expression Profiling 27
• Sequence Analysis, RNA 2
• Whole Genome Sequencing 1
• Exome Sequencing 1
• Proteomics 7
• Metabolomics 4
• Flow Cytometry 40
• Immunohistochemistry 6
• Circulating Tumor DNA 1
• Xenograft Model Antitumor Assays 50
• Magnetic Resonance Imaging 14
• Machine Learning 11
• Deep Learning 8
• Cohort Studies 26
• Genome-Wide Association Study 8

• Detection of BCR::ABL1-like ALL using RT-PCR, a targeted RNA panel, and RNA sequencing.

  Leuk Res, 2026. ápr.

• Decoding the genetic complexity in a pediatric case of B-ALL through long-read genomic sequencing and RNA sequencing.

  Cancer Genet, 2025. nov.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.